BioSight
Companies
DiaMedica Therapeutics Inc. logo

DMAC

NASDAQMINNEAPOLIS, MN
DiaMedica Therapeutics Inc.

DiaMedica Therapeutics develops DM199, a drug candidate intended to treat preeclampsia, fetal growth restriction, and acute ischemic stroke. The company is in the clinical development stage, working toward regulatory approval for testing and eventual commercialization of DM199 in these therapeutic areas.

Price history not yet available for DMAC.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar